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Protein synthesis is crucial for the maintenance of
long-term-memory-related synaptic plasticity. The
prion-like cytoplasmic polyadenylation element-
binding protein 3 (CPEB3) regulates the translation
of several mRNAs important for long-term synaptic
plasticity in the hippocampus. Here, we provide evi-
dence that the prion-like aggregation and activity of
CPEB3 is controlled by SUMOylation. In the basal
state, CPEB3 is a repressor and is soluble. Under
these circumstances, CPEB3 is SUMOylated in hip-
pocampal neurons both in vitro and in vivo. Following
neuronal stimulation, CPEB3 is converted into an
active form that promotes the translation of target
mRNAs, and this is associated with a decrease of
SUMOylation and an increase of aggregation. A
chimeric CPEB3 protein fused to SUMO cannot
form aggregates and cannot activate the translation
of target mRNAs. These findings suggest a model
whereby SUMO regulates translation of mRNAs
and structural synaptic plasticity by modulating the
aggregation of the prion-like protein CPEB3.
INTRODUCTION
Persistence of memory is achieved by the growth of new synap-
tic connections that are maintained by local synthesis at the syn-
apse of key synaptic proteins (Kandel et al., 2014). In Aplysia,
local protein synthesis is regulated by the cytoplasmic polyade-
nylation element-binding protein (ApCPEB), a prion-like protein,
which mediates the persistence of long-term synaptic facilitation
by its ability to translate dormant mRNAs (Si et al., 2003, 2010). A
key feature of Aplysia CPEB is its N-terminal domain, which is
enriched in glutamine and asparagine residues (Q/N) resembling
the Q/N-rich domain of yeast prions (Si et al., 2003). As is the
case with prion proteins, Aplysia CPEB exists in at least two1694 Cell Reports 11, 1694–1702, June 23, 2015 ª2015 The Authorsfunctional states: a soluble, inactive form and an insoluble,
aggregated and active prionic form that can self-propagate. An
antibody that selectively binds the self-sustaining oligomers of
Aplysia CPEB does not interfere with the establishment of
long-term facilitation but selectively blocks its maintenance (Si
et al., 2010). These results first suggested that the prion-like
properties of Aplysia CPEB are functional and regulate persis-
tence of synaptic facilitation. The Drosophila homolog of Aplysia
CPEB, Orb2, has similarly been found to be critical for the main-
tenance of long-term memory through a prion-like mechanism
(Majumdar et al., 2012).
Mammals express four CPEB isoforms (CPEB1, CPEB2,
CPEB3, and CPEB4; Theis et al., 2003). CPEB3 contains a
Q/N-rich domain at its N-terminal and is the mammalian homo-
log of Aplysia CPEB. We found that, as with Aplysia CPEB,
mouse CPEB3 also exists in two conformational states: a soluble
and an insoluble and aggregated form. The presence of the
N-terminal domain is required for the aggregation of CPEB3
and for the maintenance of long-term memory (Fioriti et al.,
2015). Neuronal stimulation activates CPEB3 and leads to an in-
crease in its ubiquitination by the E3 ubiquitin ligase Neuralized1.
The aggregated, active forms of CPEB3 can then initiate the
translation of target mRNAs such as GluA1 and GluA2, two
crucial components in long-term synaptic plasticity (Pavlopoulos
et al., 2011; Fioriti et al., 2015). Stephan et al. (2015) describe that
mouse CPEB3 is also a prion-like protein, which can self-propa-
gate in yeast. However, whereas there is evidence suggesting
that aggregation of Drosophila Orb2 is regulated by phosphory-
lation (White-Grindley et al., 2014), how aggregation of mamma-
lian CPEB3 is regulated is unclear.
In the brain, protein aggregation is highly regulated and, when
aberrant, can lead to degenerative brain diseases (Ross and Poi-
rier, 2004). One mechanism that has been proposed to prevent
homo-oligomerization in neurons is SUMOylation of the individ-
ual moieties of the aggregation-prone proteins (Dorval and
Fraser, 2007; Krumova et al., 2011). For example, SUMOylation
of a-synuclein inhibits its aggregation in vitro and could prevent
the consequent toxicity that contributes to Parkinson’s (Kru-
mova et al., 2011). Similarly, Huntingtin, a pathogenic protein
Figure 1. CPEB3 Is SUMOylated and Aggre-
gates in Cultured Neurons
(A) Western blotting (WB) showing detergent
insolubility assay of neuronal cells stimulated for
0 and 30minwith glycine. Soluble (S) and insoluble
(I) fractions were probed with endogenous CPEB3
antibody.
(B) Graph showing the percent of CPEB3 in the
insoluble fraction as a mean of five independent
trials ± SE (t- Stud p < 0.0001).
(C) WB showing immunoprecipitation of endoge-
nous CPEB3 from cultured neurons stimulated
with glycine for 0 and 15 min (CPEB3, immuno-
precipitation using an antibody against CPEB3;
IgG, IgG negative control; In, Input). The top panel
shows WB using an antibody raised against
SUMO-2/3. The bottom panel shows WB using an
antibody raised against CPEB3.that causes Huntington’s disease when aggregated, shows less
aggregation when SUMOylated (Steffan et al., 2004).
SUMOylation is a post-translational modification that
results from the covalent attachment of SUMO-1, SUMO-2, or
SUMO-3 to lysine residues of target proteins by SUMO ligases.
As the name suggests, small ubiquitin modifier (SUMO) is
a post-translational modification similar to ubiquitination. A
constellation of proteins are SUMOylated in cells (Gareau
and Lima, 2010). In addition to its putative role in preventing
protein aggregation, SUMOylation regulates several non-aggre-
gation-related cellular processes and pathways. These include
DNA repair, transcription, trafficking of proteins, and synaptic
transmission (Gareau and Lima, 2010). Here, we find that
SUMOylation of CPEB3 regulates its oligomerization and thereby
the activity-dependent translation of some of its targets known to
be involved in synaptic plasticity.When hippocampal neurons are
in the basal state, CPEB3 acts as repressor. In this basal state, we
find that CPEB3 is SUMOylated. Following stimulation of hippo-
campal neurons, either in cultures or in vivo,CPEB3 is rapidly de-
SUMOylated. This allows the oligomerization and aggregation of
CPEB3 necessary for its activation as a regulator of translation. A
SUMO-CPEB3 chimeric protein that is uncleavable fails both to
aggregate and to induce translation of its targets.We also identify
the SUMO-2mRNA as a target of CPEB3, suggesting a regulato-
ry feedback loop between CPEB3 and SUMO-2. These results
suggest that SUMOylation serves as a negative regulator of
CPEB3 oligomerization and prevents the aggregation required
for the translation of its target mRNAs.
RESULTS
CPEB3 Is SUMOylated in Primary Hippocampal Neurons
As a first step in exploring a possible role for SUMOylation in the
aggregation of CPEB3, we determined conditions that wouldCell Reports 11, 1694–170allow ready detection of CPEB3 oligo-
merization. We found that exposure to
glycine, a glutamatergic agonist capable
of inducing long-term potentiation (LTP)
chemically (Lu et al., 2001), increasesthe level of the CPEB3 and activates the proteins in hippocampal
cultured neurons (Fioriti et al., 2015). In so doing, glycine also in-
duces translation of SUMOand at least a subset of knownmRNA
targets of CPEB3, including GluA1 and GluA2 (Fioriti et al., 2015;
Jaafari et al., 2013). Because of its ability to activate CPEB3, we
used this protocol for studying the role of SUMO in regulating the
activity and aggregation of CPEB3.
To compare the conformation of CPEB3 before and after stim-
ulation, we made use of a biochemical assay that measures the
solubility of CPEB3 in a detergent buffer. Depending on their
conformations, amyloid and amyloid-like proteins are partially
or totally insoluble in these buffers (Drisaldi et al., 2003). We acti-
vated hippocampal neurons by exposing them to glycine. Fifteen
minutes after stimulation, we harvested the neurons and divided
them into a soluble (supernatant) and an insoluble (pellet) frac-
tion by centrifugation. Compared to unstimulated conditions,
the treatment causes endogenous CPEB3 to accumulate in
the insoluble fraction, suggesting a possible oligomerization of
the protein in response to chemical activation of neurons (Fig-
ures 1A and 1B).
To determine whether SUMOylation correlates directly with
aggregation of CPEB3, we immunoprecipitated the protein and
determined to what degree it was SUMOylated before and after
exposure to glycine. Cultured neurons were harvested and lysed
in RIPA buffer, and the whole-cell lysates were subjected to
immunoprecipitation using a mouse antibody against CPEB3.
In unstimulated conditions, an antibody raised specifically
against SUMO-2/3 detected a band at approximately 100 KDa,
corresponding to the predicted molecular weight of CPEB3
covalently linked to SUMO. This indicated that, in unstimulated
neurons, when CPEB3 is mainly soluble and not aggregated, it
is SUMOylated (Figure 1C). We also found that CPEB3 can be
SUMOylated in 293 cells and in vitro and it interacts with Ubc9
(Figure S2). To study whether SUMOylation affects aggregation,2, June 23, 2015 ª2015 The Authors 1695
we next stimulated neurons with glycine. Fifteen minutes
after stimulation, we found the SUMOylation of CPEB3 to be
decreased (Figure 1C). Taken together, these results suggest
that chemical activation of CPEB3 can lead to oligomerization
and that this oligomerization is correlated with a decrease in
SUMOylation of CPEB3.
Learning Decreases SUMOylation of CPEB3 in
Hippocampal Extracts
To study further the potential role of SUMO in the aggregation of
CPEB3, we determined whether CPEB3 is SUMOylated in vivo
and whether SUMOylation is decreased following contextual
fear conditioning, a hippocampus-dependent behavioral task
that requires CPEB3 (Figure S1).
To first determine whether CPEB3 was SUMOylated in the
absence of a stimulus, we immunoprecipitated CPEB3 from hip-
pocampal extracts, and we found that, similar to cultured neu-
rons, a fraction of CPEB3 is SUMOylated in vivo in the basal
state. By contrast, 15 min after a foot shock that induces contex-
tual fear conditioning (0.6 mA for 2 s), the fraction of CPEB3 that
is SUMOylated decreases compared to control animals exposed
to the chamber, but not shocked (Figure 2A). In addition, in earlier
studies, Pavlopoulos et al. (2011) found that there was an in-
crease of in vitro monoubiquitination of CPEB3 following
neuronal stimulation. We now confirmed these findings in mice
by finding that the monoubiquitination of CPEB3 increases
following contextual fear conditioning (Figure 2B). We next
examined whether the decrease in SUMOylation of CPEB3
following foot shock is associated with increased aggregation.
Compared to hippocampal extracts from control animals, we
found that, 30 min after foot shock, there is an increase in accu-
mulation of CPEB3 protein in the insoluble fraction (Figures 2C
and 2D). Thus, CPEB3 can form oligomers following fear condi-
tioning, mirroring what we found in cultured neurons following
neuronal stimulation. Together, these experiments suggest
that a reduction in SUMOylation of CPEB3 coincides with its
aggregation.
CPEB3 protein is present both in the nucleus and in the
cytoplasm of hippocampal neurons. To test whether CPEB3 is
also SUMOylated in synapses, we performed a fractionation
assay and purified synaptosomes from hippocampal and
cortical tissue of adult mice (Figure 2E). We then immunoprecip-
itated CPEB3 from the synaptosome preparation (Figure 2F)
and probed for SUMO-2/3. We found that CPEB3 is also
SUMOylated in the synaptosomal fraction, suggesting that
SUMOylation of CPEB3 could regulate local protein synthesis
at the synapses (Figure 2F). To determine whether CPEB3 pro-
tein can form aggregates at the synapse, we subjected the syn-
aptosomal fraction to detergent insolubility assay. We found
CPEB3 both in the supernatant and in the insoluble fractions,
suggesting that it can form amyloid-like aggregates at synapses
(Figure 2G).
SUMOylation Affects CPEB3 Aggregation Both In Vitro
and In Vivo
To study the role of SUMOylation in the aggregation of CPEB3
more directly, we made a chimeric protein, in which CPEB3 is
fused to an uncleavable SUMO-2. Based on our previous results,1696 Cell Reports 11, 1694–1702, June 23, 2015 ª2015 The Authorswe predicted that the presence of SUMO at the N terminus of
CPEB3 would prevent its aggregation.
We first tested the aggregation properties of CPEB3 and
SUMO2-CPEB3 in an in vitro assay. We translated CPEB3,
SUMO-1-CPEB3, and SUMO-2-CPEB3 in vitro and performed
a detergent insolubility assay using two different concentrations
of SDS: 0.1% and 0.2%. We found that, when fused in frame to
CPEB3, SUMO-2, but not SUMO-1, increased its solubility at
both concentrations, with a stronger effect at higher detergent
concentrations (Figure 3A). This result is consistent with previous
findings showing that a stronger detergent buffer has more
disaggregation capabilities than a milder one (Drisaldi et al.,
2003; Lehmann and Grassi, 2004). We next overexpressed
CPEB3 and SUMO-2-CPEB3 in 293 cells and performed
the detergent insolubility assay. We found CPEB3 to be in both
soluble and insoluble fractions, and compared to CPEB3 alone,
the presence of SUMO-2 increased the solubility of CPEB3
(Figure 3B).
These findings prompted us to characterize further the differ-
ences in oligomeric state between CPEB3 and SUMO-2-CPEB3
by performing a native agarose gel analysis, a technique that
allows one to study the prion-like properties of proteins. In
contrast to a detergent insolubility assay, an agarose gel allows
the discrimination of different species of insoluble aggregates
with dissimilar molecular weight, thus allowing a better resolution
of the aggregates formed by CPEB3 and by SUMO-2-CPEB3
(Bagriantsev et al., 2006). We found that, whereas overex-
pressed CPEB3 formed a smear throughout the lane, suggesting
that the protein exists in different aggregated forms, SUMO-2-
CPEB3 formed a much more restricted smear, indicating the
inability of the protein to form heavy-molecular-weight oligomers
(Figure 3C). These findings suggest that SUMO-2-CPEB3 does
not block oligomerization of CPEB3 completely but only inhibits
the formation of the largest oligomers. Taken together, these ex-
periments suggest that CPEB3 forms amyloid-like aggregates
both in vitro and in cells and that SUMO-2 prevents the formation
of the highest-molecular-weight subset of them.
To study further the role of SUMO-2 in negatively regulating
the aggregation of CPEB3, we cotransfected CPEB3 and
SUMO-2 in HeLa cells. We found that overexpression of
SUMO decreases the amount of CPEB3 in the insoluble fraction,
whereas overexpression of the SUMO-specific protease SENP2
increases the amount of CPEB3 in the insoluble fraction (Fig-
ure 3D). These experiments support the idea that inducing
SUMOylation of CPEB3 increases its solubility, whereas
decreasing its SUMOylation enhances its insolubility. Together,
these experiments illustrate that the SUMOmachinery regulates
CPEB3 aggregation.
SUMOylation of CPEB3 Affects Its Target Expression
To test whether aggregation and SUMOylation regulate CPEB3
mRNA targets, we decided to overexpress either CPEB3 or
SUMO-2-CPEB3, and we tested the expression of CPEB3
targets after neuronal stimulation. We overexpressed CPEB3
andSUMO-2-CPEB3 togetherwith the actin 30 UTR reporter plas-
mids in hippocampal neurons (Stephan et al., 2015). Following
stimulationwithglycine,we found that, in contrast to theactivation
that occurs when CPEB3 itself is expressed, SUMO-2-CPEB3
Figure 2. Fear Conditioning Induces CPEB3 Aggregation and a Decrease of SUMOylation in the Hippocampus
(A)WB showing immunoprecipitation of endogenous CPEB3 from hippocampal extracts 30min after chamber exposure and foot shock (FS). The experiment was
done in duplicate. An antibody raised against SUMO-2/3 was used in the top panel. The bottom panel shows WB using an antibody raised against CPEB3.
(B) WB showing immunoprecipitation of endogenous CPEB3 from hippocampal extracts 30 min after chamber exposure and FS. An antibody raised against
ubiquitin was used in the top panel. CPEB3 was used for the bottom panel.
(C) WB showing detergent insolubility assay of hippocampal extracts 30 min after chamber exposure or foot shock. S and I fractions were probed with antibody
against endogenous CPEB3.
(D) Graph showing the percentage of CPEB3 in the insoluble fraction as a mean of three independent trials ± SE (t-Stud p = 0.023).
(E) WB showing the fractionation of cortical and hippocampal tissue in P1 (nuclear fraction), S1 (cytoplasmic fraction), and P2 (synaptosome fraction and
mitochondria).
(F) Immunoprecipitation of CPEB3 from synaptosome fraction (P2).
(G) WB showing detergent insolubility of CPEB3 and PSD95 in synaptosomes (P2).inhibited induction of the target luciferase mRNA (Figure 4A).
These findings indicate that SUMOylation not only prevents
CPEB3 aggregation but also prevents the translation of the target
mRNAsofCPEB3.Wenext examined theeffect ofoverexpressing
CPEB3 and SUMO-2-CPEB3 on the formation of filopodia,Cefollowing stimulation (Pavlopoulos et al., 2011). We found that
glycine rapidly increases the number of dendritic filopodia, the
precursors of dendritic spines (Alvarez and Sabatini, 2007; Segal,
2005). Cells overexpressing CPEB3 showed an increase in
the number of filopodia compared to untreated control 30 minll Reports 11, 1694–1702, June 23, 2015 ª2015 The Authors 1697
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Figure 3. SUMOylation of CPEB3 De-
creases Its Aggregation
(A) WB showing detergent insolubility assay of in-
vitro-translated CPEB3-HA, SUMO-1-CPEB3-HA,
and SUMO-2-CPEB3-HA fusion proteins in the
presence of two different concentrations of SDS
(0.1% and 0.2%).
(B) WB showing detergent insolubility assay of
HEK293 cells extracts overexpressing CPEB3-HA
and SUMO-2-CPEB3-HA fusion proteins. An HA
antibody was used to detect the constructs.
(C) Left panel shows a WB of a 2D agarose gel
showing aggregates formation for CPEB3-HA and
SUMO-2-CPEB3-HA in HEK293 cells. Right panel
shows a WB of the input material.
(D) WB showing detergent insolubility assay of
HeLa cells extracts overexpressing CPEB3 alone,
CPEB3-HA and SUMO-2, and CPEB3-HA and
SENP1.after stimulation. However, neurons expressing SUMO-2-CPEB3
failed to show an increase in filopodia, suggesting that aggrega-
tion of CPEB3 following stimulus is not only important for expres-
sion of themRNA targets of CPEB3but also for themorphological
changes that occur at the level of the synapses that underlie syn-
aptic plasticity (Figures 4B and 4C).
CPEB3 Regulates Translation of SUMO-2 mRNA in Cells
and Neurons
The 30 UTR of the SUMO-1 mRNA is thought to contain cyto-
plasmic polyadenylation elements (CPEs) that can be recog-
nized by the CPEB protein (Jaafari et al., 2013). We noticed
that the mRNA of SUMO-2 contains four putative CPEs in its 30
UTR (Figure S3A). We therefore asked whether CPEB3 could
regulate the translation of the SUMO-2 mRNA. We first cloned
the full-length 30 UTR of SUMO-2 in a luciferase plasmid and
then assessed whether overexpression of CPEB3 in HeLa (Fig-
ure S3B) or 293 cells can modulate its translation. In 293 cells,
compared to GFP alone, overexpression of CPEB3 reduced
the translation of the luciferase construct. Moreover, the muta-
tion of the CPE elements of the SUMO-2 UTR rescued the trans-
lation of the luciferase construct in the presence of overexpres-
sion of CPEB3 (Figures 4D and 4E). We next determined whether1698 Cell Reports 11, 1694–1702, June 23, 2015 ª2015 The AuthorsCPEB3 also regulates SUMO-2 mRNA
translation in neurons. We found that, in
neurons, as in immortalized human cell
lines, SUMO-2 mRNA is a target of
CPEB3. Interestingly, in hippocampal
neurons, CPEB3 suppresses SUMO-2
translation in unstimulated conditions,
whereas, following glycine treatment,
CPEB3 induces the translation of
SUMO-2 mRNA (Figures 4F and 4G).
These results suggest that CPEB3 and
SUMO-2 might regulate one another.
We summarize this analysis in a model
illustrated in Figure 5. According to this
model, SUMOylation is a dynamic post-translational modification that negatively regulates the aggrega-
tion of CPEB3. In basal, unstimulated conditions, CPEB3 is
SUMOylated and mostly soluble. After neuronal stimulation,
CPEB3 becomes deSUMOylated and more aggregated.
DeSUMOylation and aggregation are two crucial steps required
for the translation of the mRNA targets of CPEB3 and for den-
dritic filopodia formation. In addition, once active, CPEB3 can
induce translation of the SUMO-2 mRNA, suggesting a negative
feedback regulatory loop between CPEB3 and SUMO-2 pre-
sumably designed to limit the aggregation of CPEB3 in both
time and amount.
DISCUSSION
Because CPEB3 can form aggregates in yeast resembling prion-
like molecules (Stephan et al., 2015), it seemed likely that the ag-
gregation process is highly regulated in vivo. Using primary hip-
pocampal neurons, we found that, in unstimulated conditions,
CPEB3 is both soluble and SUMOylated (by SUMO-2). Following
stimulation of hippocampal neurons, SUMOylation of CPEB3 de-
creases, and this is accompanied by an enhancement of both
the levels of CPEB3 and its aggregation. A similar mechanism
is operative in vivo. Hippocampal extracts taken from control
Figure 4. SUMOylation Prevents Transla-
tion of CPEB3 mRNA Targets
(A) Luciferase assay of actin UTR in 293 with
overexpression of CPEB3 or SUMO-2-CPEB3.
n = 3 experiments; n = 8 replicates. ANOVA shows
a significant interaction between the four condi-
tions (p = 0.0003).
(B and C) Filopodia counts. Primary hippocampal
neurons express CPEB3 or SUMO-2-CPEB3.
ANOVA shows a significant interaction between
the four conditions (p = 0.0335).
(D and E) Luciferase assay of SUMO-2 UTR or
SUMO-2 CPE mutant UTR in 293 with over-
expression of CPEB3. n = 3 replicates (p < 0.0001).
(F and G) Luciferase assay of SUMO-2 UTR
in primary hippocampal neurons with over-
expression of CPEB3 and stimulation with glycine.
n = 3 replicates (p < 0.0001).animals reveal CPEB3 to be SUMOylated. By contrast, 30 min
after fear conditioning, SUMOylation of CPEB3 decreases and
the protein becomes more aggregated, consistent with the
idea that the inhibition of aggregation correlates with the degree
of SUMO-2 conjugation. To determine whether this mechanism
is causal, we explored whether a chimeric CPEB3 fused in frame
to an uncleavable SUMO-2 fails to aggregate to the same extent
as the wild-type version of the protein. Indeed, we find that this
inhibition of the aggregation prevents the translation of target
mRNAs. These experiments define SUMO as a central inhibitory
constraint of the physiological formation of the prion-like form of
CPEB3, which is essential for the maintenance of long-term
memories (Fioriti et al., 2015).
SUMO and Synaptic Plasticity
Biochemical and imaging experiments have defined SUMO as
one of many regulators of synaptic plasticity, contributing, for
example, to the regulation of receptors trafficking during the in-
duction of chemical LTP (Luo et al., 2013). Indeed, induction ofCell Reports 11, 1694–170chemical LTP in cultured neurons with
glycine induces the expression of
SUMO-1 and Ubc9 (Jaafari et al., 2013).
Here, we describe a new role for SUMO
in negatively regulating synaptic plas-
ticity. In cultured neurons, SUMOylation
of CPEB3 prevents the formation of new
filopodia following stimulation, inhibiting
the translation of CPEB3 mRNA targets.
Interestingly, we also found that CPEB3
regulates the translation of the SUMO-2
mRNA. Upon stimulation, CPEB3 is
deSUMOylated and induces the transla-
tion not only of other transcripts such as
those of GluA1 and GluA2 but also of
SUMO-2. It is therefore possible that an
increase of SUMO-2 protein levels is
required not only to regulate synaptic
plasticity but also to regulate the degree
to which CPEB3 itself is SUMOylated,thereby providing a negative feedback mechanism regulating
the activity of CPEB3 after the initial stimulus.
The Modulation of Prion-like Proteins by SUMOylation
Suggests a Connection between Functional and
Pathological Prions
We have analyzed the formation of CPEB3 oligomers in the
mouse under two different in vivo conditions: (1) in hippocampal
neuronal cells following chemical activation with glycine and (2)
in brain homogenates of the dorsal hippocampus following
training for learned fear (foot shock). In both cases, the stimuli
that trigger a transient deSUMOylation of CPEB3 precede the
formation of oligomers. Conversely, fusing SUMO in frame to
CPEB3 prevents its aggregation.
A similar role for SUMO-2 in the inhibition of aggregation has
been attributed to a-synuclein in vitro, where SUMOylation of
just 10% of the proteins dramatically affects the aggregation of
a-synuclein. Insoluble aggregates of this protein are implicated
in Parkinson’s disease, and SUMOylation is thought to prevent2, June 23, 2015 ª2015 The Authors 1699
Figure 5. CPEB3 and SUMO-2 Regulate
Each Other
SUMO-2 prevents aggregation of CPEB3 mole-
cules before treatment. DeSUMOylation of the
protein facilitates aggregation and mRNA trans-
lation. The SUMO-2 mRNA is a target of CPEB3,
and it is induced upon stimulation of neurons and
deSUMOylation of CPEB3.its aggregation in cells (Krumova et al., 2011). Thus, the disease
is thought to represent, at least in part, a failure of the inhibitory
constraint on aggregation mediated by SUMOylation.
SUMO has also been proposed to regulate aggregation of
b-amyloid and tau, two proteins found aberrantly aggregated
in Alzheimer’s disease, by affecting their expression and stabil-
ity (Lee et al., 2013). We here described the role of SUMO in
regulating the aggregation of the physiological prion-like protein
CPEB3. Although we find that physiological amyloids share
similar biophysical properties to pathological ones and both
are SUMOylated in vivo, physiological and pathological
amyloids differ in the consequence of their SUMOylation.
SUMOylation of CPEB3 is a constitutive, reversible process in
the cell, mediating a physiological function. By contrast,
SUMOylation of a-synuclein, amyloid-b, and tau might prevent
an aberrant aggregation, as it serves as a self-protective mech-
anism in these neurons.
SUMO increases the solubility of other proteins, and it is often
used to tag proteins expressed in bacteria that are insoluble and
prone to aggregation and thus difficult to purify (Peroutka III
et al., 2011). Although we still do not know how SUMO prevents
aggregation, it has been proposed that the 3D structure of
SUMO prevents the aggregation of proteins directly. It may
also affect the aggregation properties of target proteins. An alter-
native mechanism that has been proposed is that SUMO directly
affects inter- or intramolecular interactions of target proteins1700 Cell Reports 11, 1694–1702, June 23, 2015 ª2015 The Authors(Gran˜a-Montes et al., 2014; Sabate
et al., 2012). As mentioned above, our
bioinformatics analysis has not as yet
located a putative SUMO-interacting
motif in the protein sequence of CPEB3,
thereby excluding a direct interaction of
SUMO and CPEB3. It is possible, how-
ever, that SUMO prevents the binding
of CPEB3 with itself or other molecules,
thus preventing the formation of amy-
loid-like aggregates. Nevertheless, we
cannot exclude the possibility that, in
addition to SUMO, other post-transla-
tional modifications, such as phosphory-
lation, can participate in the regulation
of CPEB3 aggregates as has been sug-
gested for the regulation of protein aggre-
gation in RNA granules (Han et al., 2012;
Kato et al., 2012). There is also the ques-
tion of how CPEB3 aggregates are disag-
gregated. Whereas SUMO might have a
role in disaggregation, alternatively, it isalso possible that SUMO can only act on the soluble CPEB3
molecules, preventing them from forming aggregates.
A Model for the Regulation of Physiological Prions
Involved in Memory
Long-term memory is mediated by an increase in synaptic
strength that persists over time (Kandel et al., 2014; Si et al.,
2010). This persistence is synapse-specific and regulates local
protein synthesis. In previous work, we and others found that,
in Aplysia, Drosophila, and mice, learning leads to the activation
of the aggregation-prone molecules ApCPEB, ORB2, and
CPEB3, respectively. These proteins are translational regulators
at the synapse necessary for the maintenance of long-term
memory. Intriguingly, in each case, their activation is associated
with homo-oligomerization (Bailey et al., 2004; Si et al., 2003;
Stephan et al., 2015). Both recombinant ApCPEB and CPEB3
are soluble in urea-containing buffers, but they promptly form
aggregates in more permissive solutions with a concentration
of urea lower than 2 M. This suggests that, like other prions,
the ApCPEB and CPEB3 proteins can exist in multiple stable
conformations in the absence of any post-translational modifica-
tions. We here find that the aggregation of CPEB3 in vivo and
in vitro is restrained by SUMOylation. SUMO inhibits CPEB3 ag-
gregation and consequently impairs its activation and translation
of targets and could have a detrimental effect on memory forma-
tion when misregulated. Thus, we provide further evidence that,
following a stimulus, the aggregation of the prion-like molecule
CPEB3 is a fundamental step in the function of protein synthesis
required in memory maintenance.
Many questions remain unanswered, however. For example,
how are CPEB3 aggregates regulated? Does SUMO also have
a role in disaggregation? Or is its role limited to preventing solu-
ble CPEB3 to become part of aggregates? Moreover, is CPEB3
the only functional prion-like protein regulated by SUMOylation?
Or is this a general mechanism for limiting the aggregation of
functional prion-like proteins and perhaps even prions in general,
be they functional or pathogenic? Conversely, are there other
types of regulating mechanisms that inhibit the aggregation of
prion-like proteins besides SUMOylation? Because prion-like
proteins with a physiological function have recently also been
found in the immune system (Hou et al., 2011), it now becomes
of general interest to determine whether the capability of
SUMOylation to inhibit aggregation is unique for CPEB3 or
whether it is serving as amore general mechanism for restraining
prion-like molecules from aggregating.
EXPERIMENTAL PROCEDURES
Neuronal Stimulation
Chem-LTP was induced as described previously (Jaafari et al., 2013). Briefly,
neuronal cultures were transferred from Neurobasal growth medium to extra-
cellular solution (ECS) containing 150 mM NaCl, 2 mM CaCl2, 5 mM KCl,
10 mM HEPES (pH 7.4), 30 mM glucose, 0.5 mM TTX, and 20 mM bicuculline
methiodide. After 5 min in ECS, neuronal cultures were treated with glycine
(200 mM) for 3 min in ECS and then incubated in ECS without glycine for
different time points.
Detergent Insolubility Assay
We used a modified procedure described by Tatzelt et al. (1996). Cells and
brain homogenates were lysed for 30 min at 4C in the following buffer:
0.5% Triton X-100; 0.5% NP-40; 0.5% sodium deoxycholate; and 50 mM
Tris-HCl (pH 7.5). After debris was removed by centrifugation at 16,000 3 g
for 10 min, the supernatant was centrifuged in a TLA 55 rotor at 65,000 rpm
for 40 min. Proteins in the supernatant were precipitated with methanol, and
CPEB3 in the supernatant and insoluble fractions was analyzed by western
blotting (Chiesa et al., 1998; Drisaldi et al., 2003). For the in vitro detergent
insolubility assay, CPEB3-HA, SUMO-1-CPEB3-HA, and SUMO-2-CPEB3-
HA were in vitro translated in the TNT rabbit reticulocyte lysate system
(Promega) and incubated for 1 hr in the detergent insolubility buffer.
2D Agarose Gel
Cells were washed in ice-cold PBS and re-suspended in the protein extraction
buffer (50 mM Tris-HCl [pH 7.5], 50 mM KCl, and 10 mMMgCl2) supplemented
with 10 mM phenylmethylsulfonyl fluoride and Complete protease inhibitor
cocktail (Roche Applied Science) to prevent protein degradation. SDS-AGE
gel electrophoresis ofwhole-cell lysateswasperformedaspreviously described
(Bagriantsev and Liebman, 2004). Prior to loading on the gel, lysates (40 mg of
total protein) were incubated in the sample buffer (25 mM Tris, 200 mM glycine
[pH8.3], 2%SDS, 5%glycerol, and0.025%bromophenolblue) at room temper-
ature (25C) for 7 min. To dismantle aggregates, samples were incubated in
boiling water bath instead of the room temperature incubation.
Synaptosomes Preparation
Synaptosome preparation was done according toMunton et al. (2007). In brief,
hippocampi and cortex were dissected from 10- to 12-week-old mice and ho-
mogenized in synaptoneurosome buffer (10 mM Tris [pH 7.5], 2.2 mM CaCl2,
0.5mMNa2HPO4, 0.4 mMKh2PO4, 4mMNaHCO3, and 80mMNaCl) using a
Teflon-glass mechanical tissue grinder. The homogenate was centrifuged at
1,000 g for 5 min at 4C. The supernatant was further centrifuged at 10,000Ceg for 10 min at 4C. The synaptoneurosome and mitochondrial pellet was
next re-suspended and lysed in RIPA buffer for immunoprecipitation or deter-
gent insolubility buffer to perform a detergent insolubility assay.
Luciferase Assay
Luciferase assays were performed using the Dual Luciferase Promega Kit
following the instructions of the manufacturer. Briefly, primary hippocampal
neurons at 8/9 DIV were transfected with CPEB3 or SUMO-2-CPEB3 plasmids
with a mixture of Renilla luciferase harboring actin or SUMO UTR and Firefly
luciferase containing no UTR. Twenty-four hours after transfection, cells
were stimulated with glycine for 30 min, lysed, and dual luciferase activity
was measured. Cells were lysed in 100 ml of 13 passive lysis buffer. Twenty
microliters of the lysates were used for the quantification of Firefly and Renilla
luciferase activity using a Luminometer (Turner Design).
Filopodia Analysis
Primary hippocampal neurons at 9 DIV were transfected with CPEB3-HA
or SUMO-2-CPEB3 bi-cistronic plasmids expressing also GFP. Twenty-four
hours after transfection, cells were stimulated with glycine for 30 min and
fixed and GFP-positive cells were analyzed for filopodia. Forty-micrometer
branches per neuron were analyzed, and filopodia were counted by eye. For
each group, we counted eight neurons and four branches each.
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